在韩国接受高排泄性化疗的固体癌症患者遵守抗发指南
Ryugyoung Lee1,2, Minhee Ku1,2, Nam Kyung Je3,4
1College of Pharmacy, Pusan National University, Busan, 46241, Republic of Korea.
接受高排泄性化疗 (HEC) 的癌症患者对抗排泄指南的遵守程度有所不同. 乙环素 + 环胺 (AC) 治疗方案的坚持率高于基于思的治疗方案,突出显示需要改进抗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 高度发性化疗 (HEC) 具有显著的化学疗法诱导的恶心和吐 (CINV) 风险,影响高达90%的没有预防性抗发药的患者.
- 预防性抗治疗方案对于在接受HEC的癌症患者中管理CINV至关重要.
研究的目的:
- 分析在HEC的第一个周期中使用三种药物的预防性抗疗法.
- 评估国家综合癌症网络 (NCCN) 对抗治疗指南的遵守率.
主要方法:
- 国家住院患者样本数据库 (2016-2020年) 的回顾性分析.
- 包含使用 antracycline + cyclophosphamide (AC) 或基于 cisplatin 的 HEC 疗法治疗的固体癌症患者.
- 评估三种药物抗疗法 (神经素-1受体对抗剂,5-西胺-3受体对抗剂,德克萨米他) 和遵守NCCN指导方针.
- 后勤回归用于识别影响准则遵守的因素.
主要成果:
- 总体而言,对预防性抗药的NCCN指南的遵守率为74.3%.
- 在AC组 (87.9%) 的合规性高于西斯普拉丁组 (60.4%).
- 接受AC疗程的患者比接受西斯普拉丁的患者更有可能接受6.37倍的指导标准抗药.
- 从2016年到2019-2020年,遵循指导方针的情况下降了.
结论:
- 在接受HEC治疗的患者中,很大一部分接受了符合指导方针的抗治疗.
- 在AC和cisplatin疗法之间坚持率的变化需要有针对性的干预措施.
- 优化抗emetic治疗和改善坚持是提高患者护理和管理CINV至关重要的.
更多相关视频
10:31Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
Published on: August 9, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
